info:eu-repo/semantics/article
Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells
Date
2018-05-04Registration in:
Alonso, Eliana Noelia; Ferronato, María Julia; Fermento, María Eugenia; Gandini, Norberto Ariel; López Romero, Alejandro; et al.; Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells; Impact Journals; Oncotarget; 9; 34; 4-5-2018; 23396-23412
1949-2553
CONICET Digital
CONICET
Author
Alonso, Eliana Noelia
Ferronato, María Julia
Fermento, María Eugenia
Gandini, Norberto Ariel
López Romero, Alejandro
Guevara, Josefina Alejandra
Facchinetti, Maria Marta
Curino, Alejandro Carlos
Abstract
Triple-negative breast cancer (TNBC) is associated with poor prognosis, high local recurrence rate and high rate of metastasis compared with other breast cancer subtypes. In addition, TNBC lacks a targeted therapy. This scenario highlights the need for novel compounds with high potential for TNBC treatment. In this regard, natural products are important sources of anticancer drugs. D-Fraction, a proteoglucan extracted from the edible and medicinal mushroom Grifola frondosa (Maitake), is a dietary supplement that has been shown to exert both immunostimulatory and immune-independent antitumoral effects on some cancer types. However, its antitumoral potential in TNBC is unknown. Therefore, we employed TNBC cells to investigate if D-Fraction is able to attenuate their aggressive phenotype. We found that D-Fraction decreases MDA-MB-231 cell viability through apoptosis induction and reduces their metastatic potential. D-Fraction increases cell-cell adhesion by increasing E-cadherin protein levels and β-catenin membrane localization, and increases cell-substrate adhesion. D-Fraction also decreases cell motility by affecting actin cytoskeleton rearrangements, and proteolytic activity of MMP-2 and MMP-9. Furthermore, D-Fraction decreases the invasive capacity of MDA-MB-231 cells. In concordance, D-Fraction retards tumor growth and reduces lung metastases in a xenograft model. Altogether, these results suggest the potential therapeutic role of D-Fraction in aggressive TNBC.